Saturday 17 October 2026 Export LIANY’s income statement to Excel — free account

LianBio Sponsored ADR

0.05 0.00 0.00%

Follow LIANY

Alert me

Market cap: $34.2M
P/E: 0.0×
Fwd P/E: —
Dividend yield: 0.00%
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 2.92%

Capital & Financial Ratios $m

Market Cap 34.19

Revenue —

Net Income 311.41

Free Cash Flow 258.79

Net Debt (567.37)

Current Ratio 17.03

Debt/Equity 0.00

P/E ratio 0.02

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.01

Past 5Y EPS Growth —

This Y EPS Growth 17.65%

Next Y EPS Growth 57.14%

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 6.65%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.00

Annual Dividend Yield 0.00%

	total	individual payouts
2025	0.00	0.43
2024	4.80	4.80
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	2025
Cash	302	567	52	9
Receivables	2	40	10	10
Inventory	—	—	—	—
Other	—	—	—	—
	313	613	64	21

	2022	2023	2024	2025
Payables	1	4	0	—
ST’ Debt	—	—	—	—
Other	0	3	1	—
	24	36	1	0

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(58.82%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	5
’24	—	—	—	—	4
’23	(18)	(19)	(16)	312	259
’22	(13)	(39)	(16)	(31)	(99)
’21	(2)	(93)	(39)	(30)	(164)
’20	—	—	(49)	(49)	(98)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	5
’24	—	—	—	—	4
’23	(18)	(19)	(16)	312	259
’22	(13)	(40)	(17)	(31)	(101)
’21	(2)	(93)	(39)	(31)	(165)
’20	—	—	(50)	(49)	(99)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	0.04
’24	—	—	—	—	0.02
’23	(0.22)	(0.20)	(0.22)	3.52	2.87
’22	(0.26)	(0.39)	(0.20)	(0.17)	(1.02)
’21	(3.01)	(4.90)	(0.63)	(0.28)	(5.71)
’20	—	—	(11.71)	—	(11.58)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	5.86	1.07	1.33	0.24	0.03	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	16.37	6.48	4.78	4.99	0.44
People
People	Employees	—	—	—	—	87	107	163	—	—	—
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	—	—	—
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	0.00	0.00	0.00	—	—	—
	EBT	—	—	—	(24)	(140)	(196)	(111)	311	2	5
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	(24)	(140)	(196)	(110)	311	2	5
	Depreciation	—	—	—	—	0	1	1	1	1	—
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	(0.22)	(11.58)	(5.71)	(1.02)	2.89	0.02	0.04
	Cash flow	—	—	—	(0.11)	(8.14)	(4.77)	(0.92)	2.40	0.03	0.05
	Capex	—	—	—	0.00	(0.07)	(0.03)	(0.02)	0.00	0.00	0.00
	Free cash flow	—	—	—	(0.11)	(8.22)	(4.79)	(0.94)	2.40	0.03	0.05
	Book value	—	—	—	0.36	(8.14)	11.26	2.72	5.39	0.58	0.19
	Shares, m	—	—	—	108	12	34	108	108	108	109
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(12)	(98)	(164)	(99)	259	4	5
	Capex	—	—	—	—	(1)	(1)	(2)	0	—	—
	Free cash flow	—	—	—	(12)	(99)	(165)	(101)	259	4	5
Balance, $m
Balance, $m	Working capital	—	—	—	40	271	385	289	577	63	21
	Total debt	—	—	—	1	2	5	4	—	—	—
	Net debt	—	—	—	(43)	(254)	(383)	(302)	(567)	(52)	(9)
	Shareholders’ equity	—	—	—	39	(98)	387	294	581	63	21
Returns, %
Returns, %	ROA	—	—	—	(111.09)	(86.40)	(55.64)	(29.56)	66.19	0.73	11.63
	ROIC	—	—	—	0.00	0.00	(2,990.73)	0.00	(450.47)	(217.43)	(7.12)
	ROE	—	—	—	32.79	245.17	(135.72)	(32.39)	70.96	0.77	11.75

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EDSA Edesa Biotech, Inc.	$36.1M	— (loss-making)	— (loss-making)	−99.88% (below 0%: shrinking)	n/m	−81.24% (below 0%: shrinking)	0.00%	0.00%	Compare
NNVC NanoViricides, Inc.	$35.0M	— (loss-making)	—	—	n/m	−23.94% (below 0%: shrinking)	0.00%	0.00%	Compare
LIANY LianBio Sponsored ADR	$34.2M	0.0×	—	—	n/m	+1,107.59% (above 0%: growing)	0.00%	0.00%
CRVO CervoMed Inc.	$34.0M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−6.20% (below 0%: shrinking)	100.00%	0.00%	Compare
IRLA Quince Therapeutics, Inc.	$33.8M	— (loss-making)	—	—	n/m	−63.65% (below 0%: shrinking)	0.00%	0.00%	Compare
ALGS Aligos Therapeutics, Inc.	$33.7M	— (loss-making)	— (loss-making)	+2,778.55% (above 0%: growing)	n/m	−59.81% (below 0%: shrinking)	100.00%	(6.80%)	Compare
ATNM Actinium Pharmaceuticals, Inc.	$33.3M	3.1×	— (loss-making)	+77,677.78% (above 0%: growing)	n/m	−4.91% (below 0%: shrinking)	100.00%	78.76%	Compare
BCTX BRIACELL THERAP	$32.8M	1.5×	—	—	n/m	+0.21% (above 0%: growing)	0.00%	0.00%	Compare
GNTA Genenta Science S.p.A. Unsponsored ADR	$32.3M	—	—	—	—	+35.94% (above 0%: growing)	0.00%	—	Compare
Median of peers	$33.7M	—	—	+1,339.48%	—	−15.07%	0.00%	0.00%

All 614 Biotechnology stocks →